Paul Singer Biomarin Pharmaceutical Inc Transaction History
Elliott Investment Management L.P.
- $14.9 Billion
- Q1 2025
A detailed history of Paul Singer (Elliott Investment Management L.P.) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Elliott Investment Management L.P. holds 3,500,338 shares of BMRN stock, worth $209 Million. This represents 1.66% of its overall portfolio holdings.
Number of Shares
3,500,338
Previous 3,500,338
-0.0%
Holding current value
$209 Million
Previous $230 Million
7.55%
% of portfolio
1.66%
Previous 1.41%
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
665Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.36 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.13 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.06 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$892 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$644 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...